trial · primary record
fianlimab
Melanoma
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 560 |
| Primary completion | 2033-07-10 |
| Primary endpoint | Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 based on blinded independent central review (BICR) |
| Registry ID | NCT06246916 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:42.751Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06246916
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.